Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

LY3295668

Generic Name: LY3295668

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆ClF_₂N_₅O_₂

CAS Number: 1919888-06-4

Unique Ingredient Identifier: 1WX8O5XV4R

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Posted: 2021/08/23

Sponsor:M.D. Anderson Cancer...

ID:NCT05017025

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Phase 1

Active, not recruiting

Posted: 2019/09/26

Sponsor:Eli Lilly and Compan...

ID:NCT04106219

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Phase 1

Completed

Posted: 2019/05/20

Sponsor:Eli Lilly and Compan...

ID:NCT03955939

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Phase 1

Completed

Posted: 2019/04/02

Sponsor:Eli Lilly and Compan...

ID:NCT03898791

A Study of AK-01 (LY3295668) in Solid Tumors

Phase 1

Completed

Posted: 2017/03/28

Sponsor:Eli Lilly and Compan...

ID:NCT03092934

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy